Montreal-based Eli Health has secured CAD $17 million in Series A funding to introduce its hormone-monitoring technology.
The funding round was led by BDC Capital’s Thrive Venture Fund with participation from new investors such as Accelia Capital and Telus Global Ventures, alongside existing ones like Muse Capital and Real Ventures.
A Fasken team composed of Adam Saskin, Dalia Tullio and Emilie Barreca advised Eli Health in this funding.
Adam Saskin
Partner | Corporate/Commercial, Real Estate
Montréal, QC
+1 514 397 4343
Dalia Tullio
Associate | Corporate/Commercial
Montréal, QC
+1 514 397 5115
Émilie Barreca
Associate | Emerging Technology & Venture Capital, Corporate/Commercial
Montréal, QC
+1 514 657 8781